Urology Times staff

“Concerningly, when we look at our community population, more than a third just didn't know where to go,” says Raveen Syan, MD, FPMRS.

“Where we are with this, I think that our results do not support the theory that agonists have a higher cardiovascular risk than antagonists,” says E. David Crawford, MD.

"In this study, we sought to evaluate the utility of a non-invasive biomarker—ctDNA—in predicting muscle-invasive and non–organ-confined staging of upper tract urothelial carcinoma," says Heather L. Huelster, MD.

“Providers can use this information to counsel patients that that initial sticker shock goes away once you stick with that medication,” says Katherine Shapiro, MD.

"We're calling upon urologists and primary care physicians to start the conversation and normalize discussion about erectile dysfunction with their patients before they fall through the cracks and ended up victims of these predatory online services," says Jack Vercnocke, MD.

"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.

"The main thing that we were surprised by was that at this point in time, ChatGPT couldn't give us consistent results," says Athena Barrett.

"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.

“When you're talking about Medicare patients who are on multiple medications, and this is not the only thing that they're taking, to pay over $100 for 1 medication is sometimes not possible,” says Katherine Shapiro, MD.

“Company 3 was the most surprising; the cost was $5220 per year for 10 20-mg [tadalafil] pills per month,” says Jack Vercnocke, MD.

"It's really a monumental change for patients, and it is a massive win for our health care system," says Benjamin Pockros, MD.

“We also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC,” says Nirmish Singla, MD, MSc.

Alexandra Sokolova, MD, explains the importance of genetic testing for patients with high-risk localized and advanced prostate cancer, as well as for their high-risk family members.

“Our aim overall is to describe Medicare Part D prescription drug coverage and use of prior authorization and step therapy for these medications,” says Katherine Shapiro, MD.

"We really have to think beyond just the individual health impact to understand what's underlying these disparities," says Raveen Syan, MD, FPMRS.

“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.

“We looked at the costs of various quantities and strengths of sildenafil citrate [Viagra] and tadalafil [Cialis] from 3 three well-known direct-to-consumer online pharmacies, and we compared them to Cost Plus Drugs, an online pharmacy known for its competitive wholesale pricing,” says Jack Vercnocke, MD.

"It's not just teaching all about prostate cancer; it's real life and how people are experiencing prostate cancer," says David F. Mobley, MD.

"Although there may be some variety in prevalence and severity of disease, what's most striking is when we know a patient has that diagnosis, we have consistently found that minority women are less likely to receive treatments for overactive bladder," says Raveen Syan, MD, FPRMS.

"This is a whole other approach to treating patients with this cancer. If you think about that from the perspective of prostate cancer as a whole, this is a big deal," says Thomas A. Hope, MD.

“The goal of our work, essentially, was to leverage a national population-based cancer registry to comprehensively analyze multiple socioeconomic determinants of racial disparities and survival outcomes among nearly 400,000 patients with renal cell carcinoma,” says Nirmish Singla, MD, MSc.

"We had very high specificities. The specificities amongst the 3 readers ranged from 92% to 96%," says Phillip H. Kuo, MD, PhD, FACR.

“There are always other aspects of care other than that immediate treatment period that's needed,” says Samuel L. Washington III, MD.

"Overall, we found that there was a high detection rate in patients with PSA less than 1 ng/mL," says Ashesh B. Jani, MD, MSEE, FASTRO.

“In the bladder cancer field, there's been a renewed shift on looking at environmental exposures,” says Kyle A. Richards, MD, FACS.

"We'll have to obviously amend this document quickly as these drugs move earlier in the stage of disease," says Thomas A. Hope, MD.

"We're just trying to figure out ways to reduce our readmission rate, ways to reduce complications, and I think this is just a small step in doing that," says Randie White, MD.

“One of the things that the SMSNA does really well is promote, obviously, a lot of important learning, but also a lot of opportunities for networking,” says Matthew Ziegelmann, MD.

“We wound up finding that there was no difference in recurrence, no difference in secondary events, and no difference in our survival end points whether or not you were exposed to Agent Orange,” says Kyle A. Richards, MD, FACS.